Furling group

Our research, within the REDs team, focuses mainly on 2 complementary areas:

. Understanding the molecular and cellular mechanisms involved in the pathophysiology of DM1 induced by the expression of abnormally repeated triplet CTGs and, more specifically, in alterations in muscle function.

. The development of innovative therapeutic approaches to inhibit the toxicity induced by RNAs containing expansions of pathological triplets, and their evaluation using cell and mouse models of DM1.

In addition, the effects of muscular exercise, in combination with gene therapies, are also being evaluated in mouse models of neuromuscular diseases, under the expertise of Prof. Ferry.

 

 

Group members

Denis FURLING, PhD, DR CNRS, Team leader
Ludovic ARANDEL, PhD, IR AIM
Arnaud FERRY, PhD, PU
Arnaud KLEIN, PhD, CR INSERM
Gilles MOULAY, PhD, IR AIM
Frédérique RAU, PhD, CR INSERM
Alain SUREAU, PhD, CR INSERM
Aurélien CORDIER, Msc, IE
Julie FAGIOLI, PhD student
Xavière LORNAGE, PhD, Post-doctoral fellow
Célia MARTIN, apprentice
Florent PORQUET, PhD, Post-doctoral fellow
Krizia RONQUILLO, apprentice
Corentin ROUXEL, Msc, IE

Contactdenis.furling@sorbonne-universite.fr

 

Last publications

Other publications
http://www.ncbi.nlm.nih.gov/pubmed/?term=Furling+D